More Americans are concerned about the flu than about coronavirus, according to a poll from The Associated Press-NORC Center for Public Affairs Research. Many Americans are confident in the government’s ability to handle the coronavirus, with 35% saying they have a great deal of confidence. (Associated Press)

Gilead has lost another patent challenge against its HIV prevention drug. Gilead is attempting to overturn two patents held by the Centers for Disease Control and Prevention for PrEP. The CDC funded some research on the preventive treatment. (STAT)

Lawmakers are urging health officials not to give exclusivity to coronavirus treatment makers. Forty six members of Congress said in a letter that the Department of Health and Human Services should not issue exclusive licenses to makers of coronavirus treatments over concerns about cost and accessibility for the treatment. (STAT)

Bausch Health has posted a $1.5 billion net loss in Q4. That loss is wider than the previous year, when Bausch, formerly Valeant, reported a loss of $344 million. The company’s overall revenue grew to $2.224 billion. (MarketWatch)

Teva’s neurology drug Austedo has failed two late-stage studies in Tourette syndrome. The drug did not reduce motor and verbal tics in children with moderate to severe Tourette’s. Austedo is already approved to treat involuntary movements associated with Huntington’s disease. (BioPharma Dive)